Status:
COMPLETED
Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Conditions:
Hypertension
Eligibility:
All Genders
19+ years
Brief Summary
The purpose of this study is to evaluate the effect of home blood pressure monitoring on controlling blood pressure and correlation between home blood pressure and clinic blood pressure in hypertensiv...
Detailed Description
A multi-center, cluster-randomized, prospective, observational study
Eligibility Criteria
Inclusion
- Subjects who voluntarily signed informed consent for participating in this clinical study
- Male and female over the age of 19
- Hypertensive patients receiving two or more concomitant anti-hypertensive agents including fimasartan
Exclusion
- Renal dialysis patients.
- Diabetic nephropathy patients taking angiotensin-converting enzyme inhibitor.
- Severe renal disorder
- Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
- Medical history with hypersensitivity to Fimasartan
- Pregnant women or lactating female.
- Participate in another clinical trial.
Key Trial Info
Start Date :
August 9 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2019
Estimated Enrollment :
3554 Patients enrolled
Trial Details
Trial ID
NCT03254914
Start Date
August 9 2017
End Date
February 28 2019
Last Update
December 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul national university hospital
Seoul, South Korea